A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder ...

The program, called THRIVE, will back seven different teams pursuing various groups of conditions affecting different organ systems.

ARPA-H gene editing program THRIVE awards $160 million to seven research teams tasked with building scalable base-editing platforms for rare pediatric genetic diseases — covering liver, blood, brain, ...

A Nashville doctor helped pioneer an FDA approved "state-of-the-art" gene-editing therapy that could be a cure for painful ...

ARK Invest CEO Cathie Wood joins ‘Mornings with Maria’ to discuss why she's increasing investments in SpaceX and defense ...

By identifying the genes and molecules crucial to resistance in American chestnuts and other species, researchers hope to use ...

Anya ending explained reveals whether Seymour gene-edited Libby’s egg, how Marco’s Narval genetics caused the miscarriages, ...

Buffett’s casino comments raise an uncomfortable truth. Is biotechnology an investment, or is it more of a gambling casino?

Massachusetts' biggest nursing strike ever, tackling the male loneliness epidemic, and other health news for Morning Rounds ...

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was ...

The Boston-based drugmaker has been on a mission to build out the next generation of drug products beyond its cystic fibrosis portfolio.